FDA promises Roche a snap decision on Tecentriq triple for frontline lung cancer as it falls even further behind Merck, Bristol-Myers

Roche is getting some help from the FDA in its quest to start making up some of the multibillion-dollar distance that separates the global player from Merck and Bristol-Myers Squibb in the blockbuster rivalry over the lung cancer market.